Kevin Tin, MD
Gastroenterology · Brooklyn, NYNPI 1174812044
Payments from drug & device makers
Across 702 payments — averaging $525.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$177K
- Gilead$56K
- AbbVie$34K
- Phathom Pharmaceuticals, Inc.$33K
- Madrigal Pharmaceuticals$31K
- Takeda Pharmaceuticals U.S.A., Inc.$24K
- plus $14K from 35 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$368,991 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Brooklyn
- Igor GrosmanBrooklyn$2.8M
- Alexander BrunBrooklyn$505K
- Sam MoskowitzBrooklyn$332K
- Michael GerdisYonkers$11.9M
- David HudesmanNew York$3.6M
- Ellen ScherlNew York$2.9M
- Bruce SandsNew York$2.8M
- Arun SwaminathNew York$2.7M
- Sonal KumarNew York$2.3M
- David Carr LockeNew York$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.